STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment
Tenax Therapeutics will soon report results from a Phase 3 study that is one of the biggest binary biotech stock events remaining in the sector this year.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.